SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?


To: Jay D. who wrote (540)3/26/1998 2:40:00 PM
From: E  Read Replies (1) | Respond to of 4140
 
I sent the following email to JDN. If there are any specific points anyone would have liked emphasized, let me know and I can send a followup message.I have never talked to Susan Lorigan, Sunrise's investor relations person. I hope she is a good contact number to have offered. Some IR people are very informed and helpful, I've found, and others are basically receptionists who will send you a packet if you insist.

Dear JDN:

This is to suggest for The Team's consideration, Sunrise Technologies (SNRS).

Their website contains descriptions of their opthalmic treatment systems, recent press releases, Wall Street coverage information (Red Chip and Penn.Merchant), etc. It is:

sunrise-tech.com

Their investor relations person is Susan Lorigan, 510/623-9001

There is a Sunrise Technologies thread on SI:

Subject 8695

The Sunrise thread participants are counting days in hopeful expectation of Nasdaq qualification in the not too distant future (and of course eventual marginability.)

One SNRS shareholder who went to Boca Ratan to observe the procedure (and has been buying heavily), "Nanny," has posted a number of informative (and exhuberant) messages. She describes the constituency for this technology and how the technology differs from that of its "competitors." I don't think it's a stretch to compare Sunrise to TAVA in this regard. TAVA is the only game in town for embeds, SNRS will be the treatment of choice for the farsighted, aka "hyperopes," and for treatment of the overcorrected myopic patients of VISX or BEAM . You can get more detail about the procedure and its costs, benefits, etc. from the above website and from investor relations, and the following links to posts by Nanny on the SI SNRS thread make for some good initial reading.


Message 2576202

Message 2580335

Message 2632593

Message 2648768




To: Jay D. who wrote (540)3/26/1998 8:06:00 PM
From: Michael Theye  Respond to of 4140
 
Jay,

I did take notes. However, I am off to the Bahamas in the morning and i'm trying to get the kids situated and myself packed. There was nothing spectacular that came out of the conference. However, it would be a great listen for anyone just entering the stock.

Take Care, Mike